Computational Drug Repurposing

Single-cell genomics.
Novel therapeutics.
67 patent-pending pipelines.

Ritschel Research applies a standardized scRNA-seq pipeline to publicly available human tissue datasets, identifying novel drug-target candidate pairs at single-cell resolution across autoimmune disease, neurodegeneration, oncology, and fibrosis.

Discuss Licensing

Portfolio Coverage

Disease-specific single-cell analyses across seven categories.

Autoimmune & Inflammatory

SLE · RA · IBD · MS · Sjögren's · Psoriasis · AD · CREST subtypes

Neurodegeneration

Alzheimer's · Parkinson's · ALS · Huntington's · FTD

Pulmonary & Fibrotic

Scleroderma · IPF · COPD · Asthma

Dermatologic & Soft-Tissue Fibrosis

Keloid · Dupuytren · Hidradenitis Suppurativa

GI & Metabolic

MASH · T1D · T2D · Endometriosis · EoE · Crohn's

Oncology

Glioblastoma · Gastric Premalignant

Additional Indications

Long COVID · CKD · Migraine · Sarcoidosis · Inflammaging

View Full Patent Registry →

Methodology

Standardized. Reproducible. Openly corrected.

scRNA-seq Input

NCBI GEO public
datasets

scVI Batch Correction

GPU-accelerated
integration

Leiden Clustering

Cell-type-specific
resolution

Wilcoxon DE

Top DE genes
per cluster

ChEMBL Screen

pChEMBL ≥7.5
bioactivity filter

Novelty Filter

PubChem patent
classification

Ranked Output

Scored candidates
+ watchlist

63 of the 67 patent specifications are archived on Zenodo (CC BY 4.0) with permanent DOIs; the remainder are pending deposit. The underlying cell-state results were re-tested in August 2026 against size- and expression-matched random gene sets, and the corrected tables and erratum are public at doi.org/10.5281/zenodo.22047623. All GEO datasets publicly available and independently reproducible. Sole inventor: Glen Charles Ritschel. Priority dates: February–August 2026.

Pipeline Validation

Independent preclinical corroboration in scleroderma. The portfolio's most developed work centers on a systemic sclerosis cell-state franchise and CREST-spectrum cluster, where candidate selection converges on the c-Abl/SRC and MEK/ERK axes in fibrosis. Independent preclinical work (Wermuth & Jimenez, PLoS One 2018) reported that bosutinib, a c-Abl/SRC inhibitor, produced dose-dependent reduction of dermal and pulmonary fibrosis and reversed the profibrotic myofibroblast gene-expression signature. This is independent work reaching a convergent conclusion about the same biology, not a claim of clinical efficacy.

Read the Independent Study →

Licensing & Partnership

Seeking option or license agreement with buyer-funded non-provisional conversion.

Full portfolio exclusivity and therapeutic-area carve-outs are available. Priority dates expire February–August 2027. One coordinated diligence cycle covers all 67 patents simultaneously — the Zenodo archive is your data room, available now.

Inventor

Glen Charles Ritschel

Organization

Ritschel Research, Tega Cay SC

[email protected]

Single-cell genomics.Novel therapeutics.67 patent-pending pipelines.